tradingkey.logo

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO

ReutersJun 1, 2025 2:46 PM

- Allogene Therapeutics Inc ALLO.O:

  • ALLOGENE THERAPEUTICS PROVIDES UPDATED PHASE 1 DATA HIGHLIGHTING DURABLE RESPONSES WITH ALLO-316 IN HEAVILY PRETREATED ADVANCED RENAL CELL CARCINOMA AT ASCO

  • ALLOGENE THERAPEUTICS INC - SINGLE DOSE OF ALLO-316 ACHIEVES 31% RESPONSE RATE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI